Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Haemonetics (HAE) shares rose 13% to $115.20 after CSL Limited (CSL) announced plans to roll out Haemonetics' plasma collection devices in US centers by 2027. The non-exclusive agreement allows CSL to use Haemonetics' devices and disposables, with full implementation details pending. Haemonetics' 2027 guidance remains unchanged, and updates on financial impact are expected in November 2026.
How this was made
The 30-second read
Why it matters
The contract provides a multi‑year revenue stream and has already moved the stock sharply higher.
Market read
First report of a major supply deal that triggered a 13% intraday rally in Haemonetics, indicating material market impact.
What to watch
The agreement is non‑exclusive and CSL retains other suppliers, limiting Haemonetics' upside.
Background
Haemonetics announced a non‑exclusive supply agreement with CSL Limited to equip US plasma collection centers with NexSys PCS devices and disposables through 2027.
Ticker impact
Shares jumped over 13% after CSL announced rollout of Haemonetics' plasma devices to US centers.
likely further upside as rollout progresses and disposables generate recurring sales
First‑report of a sizable contract with CSL, a major biotech, triggered a double‑digit price move, indicating market perception of material revenue impact.
Market effects
Strengthens the plasma‑collection equipment sector and may lift peers providing similar disposables.
Highlights US plasma collection market growth, benefiting domestic suppliers.
Shows Australian biotech CSL expanding US footprint, a cross‑border partnership of interest to global investors.
Counterpoint
If rollout delays or regulatory hurdles arise, the initial price rally could reverse.
Key entities
- companyHaemonetics
US‑listed provider of plasma collection devices.
- companyCSL Limited
Australian biotech firm operating US plasma collection centers.
